In MCF-7 mammary epithelial cells, EGF evokes transient ERK activation and proliferation, whereas heregulin (HRG) evokes sustained ERK activation and adipocytic differentiation, and constitutive oncogenic RAS evokes apoptosis. Herrero et al. (Mol Biol Cell, 2016) established that these outputs depend on where RAS is activated and for how long ERK stays phosphorylated, but left the underlying mechanisms open. This problem asks for that mechanistic explanation: (i) which phosphatases or regulatory circuits allow ERK to remain phosphorylated for hours after HRG even though upstream RAS and MEK activation is transient; and (ii) which subcellular ERK pools (beyond the nucleus and cytoplasm, e.g. membrane-proximal or mitochondrial locales) and which parallel signals such as PI3K must be co-active for sustained ERK to actually drive differentiation, since prolonging ERK phosphorylation in the nucleus or cytoplasm alone is insufficient.

Background

The RAS–ERK pathway is a central signal-transduction cascade: RAS, a small GTP-binding protein anchored to intracellular membranes, becomes GTP-loaded upon growth-factor receptor activation and recruits the kinase RAF, which activates MEK, which phosphorylates ERK (extracellular signal-regulated kinase, a MAP kinase). Activated ERK translocates to the nucleus and phosphorylates transcription factors, so both the duration and the subcellular location of ERK activity influence cell-fate decisions. MCF-7 human mammary epithelial carcinoma cells are a classic model for this: stimulation with EGF (epidermal growth factor, acting through EGFR) causes transient ERK activation and cell proliferation, whereas heregulin (HRG, also called neuregulin, a ligand of the kinase-inactive ErbB3 receptor that signals via ErbB2 heterodimers) causes sustained ERK activation and adipocytic (fat-cell-like) differentiation, measured by Oil Red O lipid staining. Herrero, Casar, Colón-Bolea, Agudo-Ibáñez and Crespo (Molecular Biology of the Cell, 2016, doi:10.1091/mbc.e15-02-0118) dissected how space and time are integrated in this system. They showed that both proliferative and differentiating RAS signals emanate exclusively from disordered regions of the plasma membrane (detergent-soluble, non-raft microdomains, distinct from cholesterol-rich lipid rafts), and that EGF can be converted into a differentiating stimulus by overexpressing HRAS only when it localizes to those disordered membrane domains. Conversely, activating endogenous RAS at the Golgi complex (the cellular organelle that processes and sorts membrane proteins, here targeted using the Golgi-tethered exchange-factor domains RASGRP1 or KDELr-Cdc25) antagonizes HRG-induced differentiation, and constitutively active (oncogenic) HRAS V12 induces apoptosis from several subcellular localizations, most strongly from disordered membrane and the Golgi. Two mechanistic puzzles were left open. First, kinetics: under HRG, RAS-GTP loading and MEK activation are transient while ERK stays phosphorylated for many hours, ruling out a positive-feedback mechanism at the pathway core and pointing instead to control of ERK dephosphorylation — for example by members of the DUSP/MKP family (dual-specificity MAP kinase phosphatases, the main enzymes that dephosphorylate ERK) or by the serine/threonine phosphatase PP2A — but the responsible phosphatase or regulatory circuit was not identified. Pertinent tools established in that paper: MXI2 (a p38 isoform that shuttles ERK to the nucleus and shields it from phosphatases), PEA15 (a cytoplasmic ERK anchor), and short hairpin RNA (shRNA) knockdown of DUSP6 each prolonged ERK phosphorylation in one compartment, yet none triggered differentiation, showing that prolonging nucleocytoplasmic ERK activity alone is not sufficient. Second, combinatorics: it remained unknown whether differentiation additionally requires sustained ERK activity at other locales (for example mitochondria or other membrane-proximal compartments) and/or co-activation of parallel pathways such as PI3K (phosphoinositide 3-kinase, whose activation was known to be required for HRG-driven MCF-7 differentiation). The downstream pathways and transcriptional programs by which Golgi-localized RAS suppresses differentiation and by which oncogenic RAS triggers apoptosis from different localizations were likewise not identified in that paper, although it did not pose their delineation as one of its open mechanistic questions. Prior quantitative work in the same EGF/HRG MCF-7 system (Nakakuki et al., Cell, 2010, doi:10.1016/j.cell.2010.03.054) had shown that knocking down dual-specificity phosphatases extends HRG-stimulated nuclear ERK activation and identified an HRG-induced repressor of c-fos transcription, without identifying a phosphatase-level mechanism that sustains ERK phosphorylation while upstream MEK activity has ceased. Reviews up to 2024 continue to describe the biochemical mechanisms linking ERK dynamics and subcellular localization to fate choice as incompletely understood.

Problem Statement

Determine the mechanistic basis by which the spatiotemporal features of RAS–ERK signaling dictate cell fate in MCF-7 mammary epithelial cells, as established phenomenologically by Herrero et al. (Mol Biol Cell, 2016; doi:10.1091/mbc.e15-02-0118). The overarching objective is to convert the paper's core phenomenological rule (prolonged ERK after heregulin → adipocytic differentiation) into identified molecular mechanisms; the contrasting EGF/transient-ERK → proliferation rule and the paper's remaining observations (constitutive RAS → apoptosis; Golgi RAS → antagonism of differentiation) are background context, and the dedicated effector mechanisms of those rules lie outside the scope of this question. The source paper leaves two linked questions mechanistically open: (1) Signal-duration control — determine the mechanism that permits ERK to remain phosphorylated for many hours after heregulin stimulation even though RAS-GTP loading and MEK activation are transient, with causal evidence that perturbing the identified mechanism alters the sustained ERK phosphorylation profile. (2) Compartmental and combinatorial sufficiency — determine both of the following: (2a) whether sustained ERK activity must additionally occur in subcellular pools beyond the nucleus and cytoplasm (e.g. membrane-proximal or mitochondrial locales); and (2b) what relationship to the sustained-ERK pool is required of a parallel pathway such as PI3K, whose activation is already required for HRG-driven differentiation (for example whether it acts upstream of, in parallel with, or in obligate co-activation with sustained ERK for adipocytic differentiation). Either part may be answered negatively (for example, that no additional compartment is required) and the overall outcome may be one-sided (only one of the two requirements holds), since prolonging ERK phosphorylation only in the nucleus (MXI2) or cytoplasm (PEA15 or DUSP6 knockdown) fails to drive differentiation.

References

  1. Herrero A, Casar B, Colón-Bolea P, Agudo-Ibáñez L, Crespo P. Defined spatiotemporal features of RAS-ERK signals dictate cell fate in MCF-7 mammary epithelial cells. Molecular Biology of the Cell (2016) 27(12):1958–1968. doi:10.1091/mbc.e15-02-0118. https://doi.org/10.1091/mbc.e15-02-0118
  2. Casar B, Badrock AP, Jiménez I, Arozarena I, Colón-Bolea P, Lorenzo-Martín LF, Barinaga-Rementería I, Barriuso J, Cappitelli V, Donoghue DJ, Bustelo XR, Hurlstone A, Crespo P. RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation. Nature Communications (2018) 9:3595. doi:10.1038/s41467-018-05941-8. https://doi.org/10.1038/s41467-018-05941-8
  3. Santra T, Herrero A, Rodriguez J, von Kriegsheim A, Iglesias-Martinez LF, Schwarzl T, Higgins D, Aye TT, Heck AJR, Calvo F, Agudo-Ibáñez L, Crespo P, Matallanas D, Kolch W. An Integrated Global Analysis of Compartmentalized HRAS Signaling. Cell Reports (2019) 26(11):3100–3115. doi:10.1016/j.celrep.2019.02.038. https://doi.org/10.1016/j.celrep.2019.02.038
  4. Herrero A, Reis-Cardoso M, Jiménez-Gómez I, Doherty C, Agudo-Ibañez L, Pinto A, Calvo F, Kolch W, Crespo P, Matallanas D. Characterisation of HRas local signal transduction networks using engineered site-specific exchange factors. Small GTPases (2020) 11(5):371–383. doi:10.1080/21541248.2017.1406434. https://doi.org/10.1080/21541248.2017.1406434
  5. García-Ibáñez Y, Riesco-Eizaguirre G, Santisteban P, Casar B, Crespo P. RAS Subcellular Localization Inversely Regulates Thyroid Tumor Growth and Dissemination. Cancers (2020) 12(9):2588. doi:10.3390/cancers12092588. https://doi.org/10.3390/cancers12092588
  6. Keyes J, Ganesan A, Molinar-Inglis O, Hamidzadeh A, Zhang J, Ling M, Trejo J, Levchenko A, Zhang J. Signaling diversity enabled by Rap1-regulated plasma membrane ERK with distinct temporal dynamics. eLife (2020) 9:e57410. doi:10.7554/eLife.57410. https://doi.org/10.7554/eLife.57410
  7. Nakakuki T, Birtwistle MR, Saeki Y, Yumoto N, Ide K, Nagashima T, Brusch L, Ogunnaike BA, Okada-Hatakeyama M, Kholodenko BN. Ligand-specific c-Fos expression emerges from the spatiotemporal control of ErbB network dynamics. Cell (2010) 141(5):884–896. doi:10.1016/j.cell.2010.03.054. https://doi.org/10.1016/j.cell.2010.03.054
  8. Momeny M, Tienhaara M, Sharma M, Chakroborty D, Varjus R, Takala I, Merisaari J, Padzik A, Vogt A, Paatero I, Elenius K, Laajala TD, Kurppa KJ, Westermarck J. DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. EMBO Molecular Medicine (2024) 16(7):1603–1629. doi:10.1038/s44321-024-00088-0. https://doi.org/10.1038/s44321-024-00088-0
  9. Lake D, Corrêa SAL, Müller J. Negative feedback regulation of the ERK1/2 MAPK pathway. Cellular and Molecular Life Sciences (2016) 73(23):4397–4413. doi:10.1007/s00018-016-2297-8. https://doi.org/10.1007/s00018-016-2297-8
  10. Deschênes-Simard X, Malleshaiah M, Ferbeyre G. Extracellular Signal-Regulated Kinases: One Pathway, Multiple Fates. Cancers (2024) 16(1):95. doi:10.3390/cancers16010095. https://doi.org/10.3390/cancers16010095
  11. Ram A, Murphy D, DeCuzzi N, Patankar M, Hu J, Pargett M, Albeck JG. A guide to ERK dynamics, part 1: mechanisms and models. Biochemical Journal (2023) 480(23):1887–1907. doi:10.1042/BCJ20230276. https://doi.org/10.1042/bcj20230276
  12. Kolch W, Berta D, Rosta E. Dynamic regulation of RAS and RAS signaling. Biochemical Journal (2023) 480(1):1–23. doi:10.1042/BCJ20220234. https://doi.org/10.1042/bcj20220234
  13. Freed DM, Bessman NJ, Kiyatkin A, Salazar-Cavazos E, Byrne PO, Moore JO, Valley CC, Ferguson KM, Leahy DJ, Lidke DS, Lemmon MA. EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics. Cell (2017) 171(3):683–695. doi:10.1016/j.cell.2017.09.017. https://doi.org/10.1016/j.cell.2017.09.017
  14. Busquets-Hernández C, Triola G. Palmitoylation as a Key Regulator of Ras Localization and Function. Frontiers in Molecular Biosciences (2021) 8:659861. doi:10.3389/fmolb.2021.659861. https://doi.org/10.3389/fmolb.2021.659861